Share on LinkedInShare on LinkedIn

ARTICLE · 07 APRIL 2010

En Banc Federal Circuit Confirms Section 112, Paragraph 1 Includes a Separate Written Description Requirement

In a 9–2 en banc decision, a majority of the U.S. Court of Appeals for the Federal Circuit reaffirmed that the U.S. Patent Laws (35 U.S.C. § 112, ¶1) impose a written description requirement separate and apart from the enablement requirement. Ariad Pharmaceuticals, Inc. v. Ely Lilly & Co.

United StatesIntellectual Property
Korey Anvaripour
Korey Anvaripour
Vera Elson
Vera Elson
Author LinkedIn connections

In a 9–2 en banc decision, a majority of the U.S. Court of Appeals for the Federal Circuit reaffirmed that the U.S. Patent Laws (35 U.S.C. § 112, ¶1) impose a written description requirement separate and apart from the enablement requirement. Ariad Pharmaceuticals, Inc. v. Ely Lilly & Co. This decision favors those who implement specific applications for basic research at the expense of those whose discoveries involve basic principles.

On March 22, 2010, the U.S. Court of Appeals for the Federal Circuit issued its en banc decision in Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Case No. 08-1248 (Fed. Cir. Mar. 22, 2010) (en banc) (Lourie, J.)—a 9–2 decision confirming that 35 U.S.C. § 112, ¶1 includes a written description requirement separate from the enablement requirement. The court explained that "[i]f Congress had intended enablement to be the sole description requirement of § 112, first paragraph, the statute would have been written differently."

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from